8-K: LENSAR Stockholders Approve Merger with Alcon Subsidiary, Paving Way for Acquisition

LENSAR, Inc. stockholders overwhelmingly approved the proposed merger with Alcon Research, LLC's subsidiary, VMI Option Merger Sub, Inc., at a special meeting held on July 2, 2025.

Summary

• LENSAR, Inc. held a virtual special meeting of its stockholders on July 2, 2025, to vote on proposals related to its merger with VMI Option Merger Sub, Inc., a wholly owned subsidiary of Alcon Research, LLC.
• As of the record date of May 15, 2025, there were 11,904,989 shares of Common Stock and 20,000 shares of Series A Convertible Preferred Stock outstanding and entitled to vote.
• A quorum was present at the Special Meeting, with 80.69% of all issued and outstanding shares entitled to vote being present virtually or represented by proxy.
• Proposal No. 1, the Merger Proposal, was approved with 15,983,846 votes for, 26,033 votes against, and 5,113 abstentions.
• Proposal No. 2, the non-binding advisory Merger Compensation Proposal for named executive officers, was approved with 14,369,161 votes for, 1,600,968 votes against, and 44,863 abstentions.
• Proposal No. 3, the Adjournment Proposal, was deemed not necessary as a quorum was present and sufficient votes were secured for the Merger Proposal, receiving 15,946,233 votes for, 62,212 votes against, and 6,547 abstentions.

Sentiment

Score: 8

Explanation: The successful approval of the merger proposals indicates a positive progression towards a significant strategic transaction for LENSAR, aligning with the company's stated objectives and providing a clear path forward for the business.

Positives

• The Merger Proposal was approved by the requisite vote of LENSAR's stockholders, clearing the path for the acquisition by Alcon Research, LLC.
• The non-binding advisory Merger Compensation Proposal was also approved, aligning executive compensation with the merger's completion.
• A strong quorum of 80.69% of eligible shares was present, indicating high stockholder engagement and participation in the strategic decision.

Future Outlook

The approval of the Merger Proposal by LENSAR's stockholders signifies a critical step towards the completion of the merger, with LENSAR expected to become a wholly owned subsidiary of Alcon Research, LLC.

Industry Context

This merger approval reflects a continuing trend of consolidation within the medical device and ophthalmology sectors, where larger players like Alcon seek to acquire specialized technologies and expand their market presence. Such acquisitions often aim to leverage synergies in research, development, and distribution, enhancing competitive positioning.

Stakeholder Impact

• Shareholders: Will receive consideration for their shares upon completion of the merger, as approved by their vote.
• Employees: Will likely be integrated into Alcon's organizational structure, potentially leading to changes in roles, responsibilities, or benefits.
• Customers: May experience changes in product support, service, or future product offerings as LENSAR's operations become part of Alcon.

Next Steps

• Completion of the merger, pursuant to which VMI Option Merger Sub, Inc. will merge with and into LENSAR, with LENSAR surviving as a wholly owned subsidiary of Alcon Research, LLC.

Key Dates

Keywords

LENSAR, Alcon Research, Merger, Acquisition, Stockholder Vote, SEC Filing, 8-K, Corporate Action, Ophthalmology, Medical Devices